Xenetic Biosciences, Inc. (XBIO)
Oxford Ledge is still expanding full research coverage of XBIO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biopharmaceutical company developing DNase and CAR T therapies to target difficult-to-treat solid tumors by addressing neutrophil extracellular traps.
SEC filings
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-13
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 10-K/A Amended annual report 2026-04-24
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-04-24
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-03-13
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for XBIO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open XBIO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.